Summary
Thirteen patients with metastatic malignant melanoma received interferon α-2a (Roferon-A) and vinblastine. The interferon dosage was increased from 3×106 IU to 9×106 IU daily in 10 weeks and thereafter 9×106 IU was administered three times weekly intrasmuscularly. Vinblastine (0.075–0.15 mg/kg) was given every third week intravenously. One of the ten evaluable patients had partial remission (PR) (11%) for 10 months. The diseases was stabilized (NC) in three patients (30%) for 3, 6 and 9 months. Progression (PD) occurred in six patients. The treatment time varied from 5 weeks to 44 weeks. The median survial time from the beginning of this combination treatment was 5 months. The most common side-effects were fever, fatigue, loss of taste, weight loss and neutropenia.
The mitogen response to phytohemagglutinin and purified protein derivative of tuberculin decreased in all patients. The response to concanavalin A decreased less and began to increase again in the patients with PR and NC. The natural killer cell activity in PD patients decreased more than in the patients with PR and NC. The ratio of T4/T8-positive cells was restored in PR + NC patients but rose in PD patients indicating a difference in the immunomodulatory effect of the combination or of the advanced disease itself on T-cell function in PD patients.
This combination of daily interferon and vinblastine did not prove to be effective in melanoma. The depression of immunological functions, which was more marked in patients with PD, might indicate that vinblastine in this combination counteracts the immunostimulatory effect of interferon.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Creagan ET, Ahmann DL, Frytak S, Long HJ, Chang MN, Itri LM (1987) Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analysis. Cancer 59:638
Eskola J, Soppi E, Viljanen M, Ruuskanen O (1975) A new micromethod for lymphocyte stimulation using whole blood. Immunol Commun 4:297
Grossman Z, Herberman RB (1986) Natural killer cells and their relationship to T-cells. Hypothesis on the role of T-cell receptor gene rearrangement on the course of adaptive differentiation. Cancer Res 46:2651
Hersey P, MacDonald M, Hall C, Spurling A, Edwards A, Coates A, McCarthy W (1986) Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma. Cancer 57:1666
Hirsch RK, Johnson KP (1986) The effect of long term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis. J Interferon Res 6:171
Jacqillart C, Banzet P, Maral J (1980) Clinical trials of chemotherapy and chemoimmunotherapy in malignant melanoma. In: Recent results in cancer research. Springer-Verlag, Berlin-Heidelberg, p 254
Jones SV, Itsi LM (1986) Safety and tolerance of recombinant interferon alfa 2-a (Roferon®-A) in cancer patients. Cancer 57:1709
Kirkwood J, Ernstoff M (1985) Melanoma: therapeutic options with recombinant interferons. Semin Oncol 12:7
Kuzmitz R, Kokoschka EM, Micksche M, Ludwig H, Flener R (1985) Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma. Oncology 42:26
Langer JA, Ortaldo JR, Petska S (1986) Binding of human alpha-interferons to natural killer cells. J Interferon Res 6:97
McLeod GR, Thomson DB, Hersey P (1987) Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I–II study in combination with DTIC. Int J Cancer 1:31
Miller AB, Hoogstraten B, Staquet MQ, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207
Pinsky CM (1984) The immunology and immunotherapy of malignant melanoma. In: Clinical management of malignant melanoma. Martinus Nijhoff Publ, Boston
Reidnegger G, Fuchs D, Hausen A, Werner ER, Wachter H (1987) Activated macrophages and cancer. Lancet 29:1439
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT et al. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485
Rusthoven JJ (1985) Clinical significance of natural killer cell cytotoxicity: need for proper data analysis in the design of clinical studies. Eur J Cancer 21:1287
Spitler LE, Sagebiel R (1980) Randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J Med 303:1143
Toivanen A, Granberg I, Nordman E (1984) Lymphocyte subpopulations in patients with breast cancer after postoperative radiotherapy. Cancer 54:2919
Veronesi U, Adamus J, Aubert C, et al. (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307:913
Veronesi U, et al. (1984) WHO collaborating centers for evaluation of methods of diagnosis and treatment of melanoma. Controlled study with imidazole carboxamide (DTIC). DTIC + bacillus Calmette-Guerin (BCG), and DTIC + Corynebacterium parvum in advanced malignant melanoma. Tumori 70:41
West WH, Cannon GB, Kay HD, Bonnard GD, Herberman RB (1977) Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol 118:355
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kellokumpu-Lehtinen, P., Nordman, E. & Toivanen, A. Combined interferon and vinblastine treatment of advanced melanoma: evaluation of the treatment results and the effects of the treatment on immunological functions. Cancer Immunol Immunother 28, 213–217 (1989). https://doi.org/10.1007/BF00204991
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00204991